Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
APG-2449 / Ascentage Pharma
ACTRN12623000174684: A Phase Ib/II Study of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in Patients with Ovarian Cancer	Recruiting	1	40			Ascentage Pharma Pty Ltd, Ascentage Pharma Pty Ltd	Ovarian Cancer
NCT06687070: APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST	Not yet recruiting	1	50	RoW	APG -2449, PLD	Ascentage Pharma Group Inc.	Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor	05/26	05/27
NCT03917043: APG-2449 in Patients With Advanced Solid Tumors	Recruiting	1	150	RoW	APG-2449, APG-2449 Capsule	Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.	Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma	01/25	02/25